SFCC - 500 Beiträge pro Seite

[BigLinus]

@Alle
Kann mir einer von Euch etwas näheres über den US-BioTech-Wert SFCC (US784121105) sagen? Bisher habe ich nur diese Nachricht im deutschsprachigen Internet gefunden.

Mittwoch, 11.07.2001, 18:27
SFBC plant mehrere Akquisitionen
SFBC International meldete am Mittwoch, dass das Unternehmen sein Akquisitionsprogramm mit dem Erwerb eines geheimen Labors zur Bioanalyse angehen wird.

Ohne die geplanten Akquisitionen erwartet SFBC einen Anstieg der Verkäufe um mindestens 40 Prozent im Jahr 2001. Im vergangenen Jahr lag der Wert bei 19,7 Mio. Dollar.

Des weiteren teilte das Management mit, zwei weitere Nischen-Provider ausfindig gemacht zu haben, die das Unternehmen erwerben möchte. Dazu sieht die Firmenleitung eine Verwendung eigener Anteile sowie angesammelter Barmittel vor.

Danke schon mal im voraus!
Ciao BigLinus

[BigLinus]

@Alle
In Deutschland hat der Wert das Kürzel SFX und wird in Berlin gehandelt (WKN: 676285).
Ciao BigLinus

[BigLinus]

Wednesday September 26, 9:29 am Eastern Time
Press Release
SOURCE: SFBC International, Inc.
SFBC International To Webcast Investment Presentation at Raymond James & Healthcare Conference
MIAMI--(BUSINESS WIRE)--Sept. 26, 2001--SFBC International (Nasdaq:SFCC - news) today announced that it will webcast the investment presentation that its management will make at the Raymond James & Associates Healthcare Conference in Nashville, Tennessee, on October 1, 2001 The presentation will be available on the SFBC`s website http://www.sfbci.com, and the Raymond James website customer.nvglb.com/raymondjames/health at 5:20 p.m. Eastern Time. Dr. Lisa Krinsky, Chairman, and Arnold Hantman, Chief Executive Officer will make the presentation.

SFBC International, Inc. is a rapidly expanding provider of specialized, outsourced drug development research services for the pharmaceutical and biotechnology industries. It has one of the largest contract research sites in the United States, and specializes in geriatrics; pediatrics; post-menopausal women; cardiac disease; diabetes; kidney disease; ophthalmology; HIV, and dermatology. Additional information is available at the company`s website at http://www.sfbci.com.

[BigLinus]

@Alle
Bisher hat leider keiner von Euch etwas gepostet. Dies entspricht auch dem Handel in Berlin.

Aber vielleicht könnt Ihr mir trotzdem weiterhelfen, allgemein aber auch konkret: Ich bin nachwievor an SFBC International interessiert, möchte aber direkt in den USA kaufen.
Was habt Ihr hier für Erfahrungen gemacht? Wie hoch sind Eure zusätzlichen Spesen für Transaktionen an der NYSE oder der NASDAQ?

Ich hoffe, ich bekomme hier zumindest nähere Infos von Euch!!
Ciao BigLinus

[BigLinus]

SFBC International

Our Business We are a specialized provider of outsourced drug development
research services for the pharmaceutical and biotechnology
industries. We have one of the largest contract research
sites in the United States today. Most of the business
conducted at that site has been Phase I and II clinical
trials and related services that variously determine and
document the safety, absorption and dosing of potential new
drugs developed by our clients. The United States Food and
Drug Administration sets forth very specific guidelines for
human clinical trials testing a potential drug or medical
product. This testing is usually done in three or four stages
known as Phase I through Phase IV.

. Phase I involves testing a drug or product on a limited
number of healthy participants to determine how the
drug or product is absorbed by and eliminated from the
body.

. Phase II involves testing a drug or product on
approximately 200 participants suffering from the
condition targeted by the drug or product to determine
the safety and effectiveness of the drug or product.

. Phase III involves testing a drug or product on a large
number of participants to determine long term and large
scale safety and effectiveness of a drug or product.

. Phase IV involves continued testing after new drug
approval, to monitor long-term effects of the drug or
product.

In March 2000, we expanded into Phase III clinical trial work
through the acquisition of the assets of Pharmaceutical
Development Associates, Inc. Phase III clinical trials are
conducted to determine the therapeutic benefit of a potential
new drug on a specific disease. We believe that the business
we acquired, which we operate through SFBC Charlotte, Inc.,
our wholly-owned subsidiary, is among the most active
providers of ophthalmology drug studies and a leading
provider of dermatology drug studies. It is also
one of few established providers of studies for potential new
generic drugs in the United States where the absorption of
the drugs into the bloodstream cannot be determined. These
studies are large-scale Phase III or Phase IV clinical trials
in which the proposed generic drug is compared to the brand
name drug. These studies began to be required by the Food and
Drug Administration in 1997.

In February 2001, we further expanded our operations through
the acquisition of ClinSites/LeeCoast Research Center, Inc.
LeeCoast Research operated a Phase I clinical trials facility
in Ft. Myers, Florida, which performed a wide range of
clinical trials primarily in the areas of generic drugs and
dermatology studies. We now conduct these operations through
our wholly-owned subsidiary, SFBC Ft. Myers, Inc.

On August 20, 2001, we expanded our business by acquiring
KeyStone Analytical Laboratories, Inc., which operated an
analytical laboratory that provided complete bioanalytical
testing and analysis of pharmaceutical products and
substances. We operate the analytical laboratory through our
wholly-owned subsidiary, SFBC Analytical Laboratories, Inc.
SFBC Analytical provides its laboratory services from its
offices in suburban Philadelphia using modern state-of-the-
art equipment.

While we have been in business for 18 years, we introduced
our current business model in 1995. Over the past six years,
we have served over 50 clients, including all of the top 25
pharmaceutical companies in the United States. We have
focused on building a reputation for producing results
rapidly in compliance with each clinical trial protocol and
the Food and Drug Administration requirements. We believe our
pharmaceutical and biotechnology clients can realize greater
financial benefits from more rapidly available valid clinical
trial results. To realize our goal, we have built and
continue to expand a database of volunteers representing a
broad range of special populations, including post-menopausal
women, children with specific diseases, and individuals who
are HIV positive able to quickly accommodate most early phase
clinical trials. In addition, SFBC Charlotte has established
physician networks in ophthalmology and dermatology. We
consider our responsiveness to clients, particularly with
restrictive, special population studies, to have been key to:
(1) attracting new clients, (2) earning the repeat business
of our established clients, and (3) capturing the unfulfilled
work of other, generally larger, contract research
organizations that do not have the ready access to the
required participants. We count among our niche expertise the




following special populations:
. Cardiac

. Diabetics
. Geriatrics

. Kidney disease

. Ophthalmology

. Pediatrics

. Liver diseases

. Post-menopausal females

. HIV positive

. Dermatology

In addition to performing Phase I through Phase IV clinical trials for pharmaceutical companies, biotechnology companies and other contract research organizations, we provide a range of other clinical research services including:

. protocol design: designing clinical trials for customers in conformance with FDA regulations;

. report writing: providing a comprehensive summary of the conduct of a study for customers submission to the FDA;


. data management: including the transfer of study data
to clinical report forms;

. institutional review board services: preparing
paperwork and all documents to be submitted to an
institutional review board for approval; and

. electronic data transfer: transferring study data to
the study sponsor instantaneously or to other data
banks via computer.

Our Strategy Our goal is to become the comprehensive provider of choice
for a widening range of specialized clinical trials. This
involves expanding the breadth of our clinical trials and
related services to provide comprehensive contract research
organization solutions. We expect to include the building and
acquisition of complementary businesses. Our strategy




includes the following key elements:

. Continue to build our proprietary database of special participant populations;
. Operate our new clinical laboratory which we expect to open in the fourth quarter of 2001;

. Continue to expand the range of services offered to our clients through acquisitions and strategic alliances; and

. Continue to recruit and train our employees.

In carrying out these strategies, we face a number of obstacles including competition from competitors of various size drawing resources from the same special populations, competition from larger companies seeking the same acquisition targets, and competition from other participants in the healthcare field seeking qualified employees.

Our executive offices and clinic are located at 11190 Biscayne Boulevard, Miami, Florida 33181, and our telephone number is [phone]. SFBC Charlotte maintains offices in Charlotte, North Carolina and in Dublin, Ireland. SFBC Ft. Myers maintains offices and operates a clinic in Ft. Myers, Florida and also has a facility in the Tampa, Florida area. SFBC Analytical is located in North Wales, Pennsylvania. Our website is located at www.sfbci.com.